GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (FRA:RGN) » Definitions » Cash And Cash Equivalents

Repligen (FRA:RGN) Cash And Cash Equivalents : €718.2 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Repligen Cash And Cash Equivalents?

Repligen's quarterly cash and cash equivalents increased from Sep. 2023 (€591.04 Mil) to Dec. 2023 (€688.96 Mil) and increased from Dec. 2023 (€688.96 Mil) to Mar. 2024 (€718.17 Mil).

Repligen's annual cash and cash equivalents declined from Dec. 2021 (€534.38 Mil) to Dec. 2022 (€494.14 Mil) but then increased from Dec. 2022 (€494.14 Mil) to Dec. 2023 (€688.96 Mil).


Repligen Cash And Cash Equivalents Historical Data

The historical data trend for Repligen's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Cash And Cash Equivalents Chart

Repligen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 475.55 589.61 534.38 494.14 688.96

Repligen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 482.51 557.17 591.04 688.96 718.17

Repligen Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Repligen  (FRA:RGN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Repligen Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Repligen's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen (FRA:RGN) Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.

Repligen (FRA:RGN) Headlines

No Headlines